Cellular senescence, which is characterized by an irreversible cellcycle arrest 1 accompanied by a distinctive secretory phenotype 2 , can be induced through various intracellular and extracellular factors. Senescent cells that express the cell cycle inhibitory protein p16 INK4A have been found to actively drive naturally occurring age-related tissue deterioration 3,4 and contribute to several diseases associated with ageing, including atherosclerosis 5 and osteoarthritis 6 . Various markers of senescence have been observed in patients with neurodegenerative diseases 7-9 ; however, a role for senescent cells in the aetiology of these pathologies is unknown. Here we show a causal link between the accumulation of senescent cells and cognition-associated neuronal loss. We found that the MAPT P301S PS19 mouse model of tau-dependent neurodegenerative disease 10 accumulates p16 INK4A -positive senescent astrocytes and microglia. Clearance of these cells as they arise using INK-ATTAC transgenic mice prevents gliosis, hyperphosphorylation of both soluble and insoluble tau leading to neurofibrillary tangle deposition, and degeneration of cortical and hippocampal neurons, thus preserving cognitive function. Pharmacological intervention with a first-generation senolytic modulates tau aggregation. Collectively, these results show that senescent cells have a role in the initiation and progression of tau-mediated disease, and suggest that targeting senescent cells may provide a therapeutic avenue for the treatment of these pathologies. ATTAC PS19;ATTAC 5 7 8 | N A t U r e | V O L 5 6 2 | 2 5 O C t O B e r 2 0 1 8
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Senescent cells accumulate with ageing and have been shown to contribute to tissue dysfunction 11 , although their role in neurodegenerative disease is still unknown. To address this key open question, we selected the transgenic mouse line MAPT P301S PS19 (hereafter PS19), whichunder the regulation of the mouse prion promoter-expresses high levels of mutant human tau specifically in neurons 10 . The model is characterized by gliosis, neurofibrillary tangle (NFT) deposition, neurodegeneration and loss of cognitive function. Pathology typically initiates in the hippocampus and radiates outwards to the neocortex 10 . First, we performed quantitative PCR with reverse transcription (RT-qPCR) for p16 Ink4a (also known as Cdkn2a) on isolated hippocampi and cortices from wild-type and PS19 littermates. A significant increase in p16 Ink4a expression was seen in the PS19 mice beginning at four months of age in the hippocampus and at six months of age in the cortex (Fig. 1a) , which precedes the onset of NFT deposition 10 . Importantly, increased expression of p16 Ink4a correlated with the expression of widely established senescence markers (Extended Data Fig. 1 ), indicating that senescent cells accumulate at sites of pathology in the PS19 model.
To investigate the role of senescent cells in the development of disease, we crossed the INK-ATTAC transgene (hereafter ATTAC) to the PS19 strain to eliminate p16 Ink4a -expressing senescent cells through the twice-weekly administration of AP20187 (hereafter AP) 3,4 from weaning age ( Fig. 1b ). Hippocampi and cortices isolated from six-month-old vehicle-administered PS19;ATTAC mice displayed an increased level of the ATTAC transgene, as measured by the expression of Casp8 and Gfp (Fig. 1c , Extended Data Fig. 2 ). Levels of senescence indicators, including the cell-cycle regulators p16 Ink4a , p19 Arf (also known as Cdkn2a) and p21 Cip1/Waf1 (also known as Cdkn1a) and the pro-inflammatory genes Pai1 (also known as Serpine1), Il6 and Il1b, were also increased ( Fig. 1c , Extended Data Fig. 2 ). Administration of AP to PS19;ATTAC mice maintained the expression of these genes at a level comparable to that of control mice ( Fig. 1c , Extended Data Fig. 2 ). Importantly, treatment of ATTAC mice that lacked the PS19 transgene with AP had no effect on the expression of these markers (Extended Data Fig. 2 ). Thus, AP administration effectively and selectively cleared senescent cells in the hippocampus and cortex of PS19;ATTAC mice.
To understand the mechanistic contribution of senescence to tau-mediated pathology, we sought to identify the specific cell types that were becoming senescent. First, we stained cortices and hippocampi from six-month-old vehicle-treated ATTAC and PS19;ATTAC mice and AP-treated PS19;ATTAC mice for senescence-associated-β-galactosidase (SA-β-Gal) 12 and screened for cells that contained 5-bromo-4-chloro-3-indolyl-β-d-galactopyranoside (X-Gal) crystals by transmission electron microscopy 13 . We found that cells that clearly and morphologically resembled astrocytes or microglia contained X-Gal crystals, irrespective of the treatment group from which they arose ( Fig. 1d ). By contrast, no crystals were found in any clearly identifiable neurons (Extended Data Fig. 3 ). Compared with control mice, vehicle-treated PS19;ATTAC mice had nearly double the number of cells containing X-Gal crystals in both the hippocampus and the cortex (Fig. 1e ), whereas AP-treated PS19;ATTAC mice had a similar incidence of X-Gal crystals as control mice (Fig. 1e ). To validate that senescence was affecting astrocytes and microglia, we performed fluorescence-activated cell sorting (FACS) on six-month-old wild-type and PS19 mice (Extended Data Fig. 4a ). Isolated astrocytes and microglia had increased expression of senescence-associated genes, including p16 Ink4a (Extended Data Fig. 4b, c ). A similar induction was not observed in oligodendrocytes or neuron-enriched CD56 + cells (Extended Data Figs. 4d, e, 5), supporting the conclusion that senescence occurs primarily in astrocytes and microglia of PS19 mice. 
To verify that the administration of AP selectively targeted senescent cells, we prepared in vitro cultures of primary microglia and astrocytes isolated from ATTAC mice. These cultures were not sensitive to AP-mediated elimination in the absence of senescence-inducing stimuli (Extended Data Fig. 6 ). Furthermore, for ATTAC transgenic mice in vivo, the short-term administration of AP did not promote excessive cellular death (Extended Data Fig. 7a ), and extended treatment with AP did not result in increased proliferation of microglia (Extended Data Fig. 7b ).
PS19 mice present progressive gliosis with disease progression 10 . To assess whether the administration of AP affected this process, RT-qPCR was performed on the hippocampi of six-month-old mice for markers of astrocytes (Gfap and S100b) and microglia (Cd11b, also known as Itgam). Vehicle-treated PS19;ATTAC mice had an approximately two-to threefold induction in these markers, whereas AP-treated PS19;ATTAC mice expressed these markers at a similar level to control mice (Extended Data Fig. 8a, b ). Immunohistochemistry staining for GFAP and IBA1 confirmed these observations (Extended Data Fig. 8c, d ). Taken together, these results suggest that both senescent glial cells and gliosis are eliminated upon the administration of AP in PS19;ATTAC mice.
A distinguishing characteristic of PS19 mice is the development of aggregates consisting of hyperphosphorylated tau protein by six months of age 10 . To assess whether tau aggregation was affected by senescence clearance, we measured the levels of soluble total and phosphorylated tau (S202/T205) in addition to the level of insoluble phosphorylated tau in vehicle-treated PS19;ATTAC and AP-treated ATTAC and PS19;ATTAC mice. As expected 10 , vehicle-treated PS19;ATTAC mice displayed increased levels both of soluble total and phosphorylated tau and of insoluble phosphorylated tau ( Fig. 2a , Extended Data Fig. 9a, b ). AP-treated PS19;ATTAC mice had identical levels of soluble total tau to vehicle-treated PS19;ATTAC mice ( Fig. 2a ), indicating that overexpression of tau from the transgene was maintained. Treatment of PS19;ATTAC mice with AP significantly reduced the amount of phosphorylated tau in both the soluble and the insoluble fractions ( Fig. 2a , Extended Data Fig. 9b ). Immunohistochemistry staining for phospho-tau modifications at S202/T205, T231 and S396 confirmed that the clearance of senescent cells attenuated tau phosphorylation at several residues that are relevant for tau aggregation (Fig. 2b , Extended Data Fig. 9c ). Additionally, the staining of brain sections of eightmonth-old mice from these same groups with thioflavin-S revealed that NFT deposition in the dentate gyrus-the site of neurogenesis in the hippocampus that is traditionally associated with memory formation and cognition 14 -was substantially reduced when senescent cells were removed ( Fig. 2c ). Collectively, these results indicate that the accumulation of senescent cells promotes the formation of hyperphosphorylated tau aggregates.
PS19 mice show neurodegeneration by eight months of age 10 . As NFT deposition was attenuated upon treatment with AP in both the cortex and the hippocampus of PS19;ATTAC mice, we performed assessments for degeneration in these areas. The overt brain size of vehicle-treated PS19;ATTAC mice was reduced compared to both 
ATTAC and AP-treated PS19;ATTAC mice ( Fig. 3a ). In addition, we observed localized neurodegeneration in the dentate gyrus of the hippocampus through Nissl staining in vehicle-treated PS19;ATTAC mice ( Fig. 3b ). The administration of AP prevented thinning of the dentate gyrus and increased neuron density. Sequential coronal sectioning and NeuN staining revealed that the dentate gyrus was significantly reduced in area in vehicle-treated PS19;ATTAC mice ( Fig. 3c ), further demonstrating that senescent cells promote neurodegeneration in PS19 mice.
To test whether the effects observed upon administration of AP resulted in improved cognitive function, we performed novel-scent discrimination assessments to test for changes in short-term memory 15 (for experimental setup, see Fig. 3d ). Whereas AP-treated ATTAC mice were more inquisitive towards the novel scent during the testing phase, vehicle-treated PS19;ATTAC mice were not ( Fig. 3d ). By contrast, AP-treated PS19;ATTAC mice behaved nearly identically to control (AP-treated ATTAC) mice, indicating that the elimination of senescent cells mitigated the short-term memory loss observed in vehicle-treated PS19;ATTAC mice. Notably, the overall distance travelled by mice in all groups was unchanged (data not shown), and similar results were obtained in novel-object discrimination tests that had the same setup but used visual cues instead of scents (Extended Data Fig. 10 ). Thus, these results demonstrate that senescent cells drive neurodegeneration and loss of cognition in PS19 mice.
Last, we tested whether the pharmacological elimination of senescent cells with the senolytic ABT263 (navitoclax) 5, 6, 16, 17 resulted in similar effects to our genetic interventions in PS19 mice. Recent work has demonstrated a therapeutic effect in orthotopically implanted glioblastomas of the peripheral administration of ABT263 18 . Wild-type and PS19 mice were treated with a repeating schedule of ABT263, beginning at weaning age and continuing until the mice reached six months of age. Notably, this treatment prevented the upregulation of senescence-associated genes ( Fig. 4a ) and attenuated tau phosphorylation in PS19 mice ( Fig. 4b ), indicating that senolytic interventions can recapitulate key observations from transgenic mouse models of senescent-cell ablation.
The mechanistic contribution of cells with features reminiscent of senescence to the pathophysiology of neurodegenerative diseases has been a common question in recent years [7] [8] [9] [19] [20] [21] . Furthermore, recent work has suggested that senescent cells may contribute to the pathology of Parkinson's disease in both mice and humans 22 . Here we show that the continuous clearance of p16 Ink4a -expressing senescent cells before disease onset in a model of aggressive tauopathy has a marked effect on various aspects of disease progression, including gliosis, NFT formation, neurodegeneration and cognitive decline. Senescent-cell clearance also has a notable effect on the accumulation of phosphorylated tau protein in both the soluble and insoluble fractions. The amount of total soluble tau was unchanged in AP-treated PS19;ATTAC mice ( Fig. 2a ), indicating that the aberrant hyperphosphorylation of tau protein and subsequent aggregation into NFTs is mediated by extracellular signalling from p16 Ink4a -expressing senescent glial cells. The molecular mechanisms that senescent astrocytes and microglia exploit to promote the pathological conversion of tau into NFTs within neurons require additional investigation. The absence of neurodegeneration in mice treated with AP ( Fig. 3 ) demonstrates that the attenuation of disease severity does not result from the clearance of neurons containing NFTs. However, it is important to leave open the possibility that other models of neurodegenerative disease may exhibit senescence-associated alterations in cell types other than those observed in the present study. Regardless, based on our observations, it is likely that intervening with senescent-cell accumulation in these models would also reduce the Letter reSeArCH severity of disease. As this study was designed to prevent senescent cells from accumulating to determine how this affects disease, future studies of senolysis in established disease models will be necessary to determine whether senolytic strategies could translate into the clinic to halt or perhaps revert disease. As senescent cells exhibit a unique and identifiable senescence-associated secretory phenotype, exploiting this phenotype may serve as a possible therapeutic avenue to attenuate many tau-dependent pathologies. Our observation that p16 Ink4a expression increases before the onset of NFT aggregation further supports the now commonly held belief that early intervention in these diseases is essential to provide more beneficial effects for patients.
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MEthodS
Mouse strains and drug treatment. MAPT P301S PS19 (PS19) mice were purchased from The Jackson Laboratory (stock no. 008169) and bred to C57BL/6 for three generations. C57BL/6 ATTAC transgenic mice are as previously described 3, 4 . Male PS19 mice were bred to ATTAC females to generate cohorts of ATTAC and PS19;ATTAC mice. All mice were on a pure C57BL/6 genetic background. Mice from this cohort were randomly assigned to receive AP20187 (AP; B/B homodimerizer; Clontech) or vehicle twice a week beginning at weaning age (3 weeks). Dosing of AP was 2.0 mg per kg body weight. Six-month-old short-term AP-pulsetreated mice (Extended Data Fig. 6a ) received a dose of 10 mg per kg body weight for five consecutive days before tissue collection. Senolytic intervention was performed in C57BL/6 wild-type and PS19 mice. At weaning, mice were assigned to receive either ABT263 (Cayman, 923564-51-6) or vehicle (Phosal 50 PG, Lipoid NC0130871, 60%; PEG400, Sigma 91893, 30%; ethanol, 10%). ABT263 was administered by oral gavage at a dose of 50 mg per kg body weight on a repeating regimen of five consecutive days of treatment followed by 16 days of rest. Mice were housed in a 12 h:12 h light:dark cycle environment in pathogen-free barrier conditions as previously described in detail 3 . Compliance with relevant ethical regulations and all animal procedures were reviewed and approved by the Mayo Clinic Institutional Animal Care and Use Committee. Statistical analysis. Prism software was used for all statistical analysis. A Student's two-tailed unpaired t-test with Welch's correction was used in Fig. 1a and Extended Data Fig. 4b-e ; two-way ANOVA with Tukey's multiple comparisons test was used for Fig. 3d and Extended Data Fig. 10 ; and one-way ANOVA with Tukey's multiple comparisons test was used in all other figures. For consistency in these comparisons, the following denotes significance in all figures: *P < 0.05, **P < 0.01, ***P < 0.001. We note that no power calculations were used. Sample sizes are based on previously published experiments in which differences were observed. No samples were excluded. Investigators were blinded to allocation during experiments and outcome assessment, except for rare instances in which blinding was not possible.
Senescence-associated β-galactosidase transmission electron microscopy (Gal-TEM).
Detection of X-Gal crystals by TEM after senescence-associated β-galactosidase (SA-β-Gal) staining was performed as previously described 3, 5 , with the following alterations to accommodate central nervous tissue. Mice were transcardially perfused with ice-cold Dulbecco's phosphate-buffered saline (DPBS; pH 7.4) until fluid run-off was clear. This was followed by perfusion with 4% paraformaldehyde (PFA) for 10 min at a rate of 3 ml min −1 , and then ice-cold DPBS was perfused again for 2 min at the same rate to remove the remaining fixative. Brains were then isolated and the hippocampus and cortex were dissected out. A 1 mm × 1 mm piece from the CA1 and M1 regions, respectively, was then incubated in SA-β-Gal staining solution (Cell Signaling) at 37 °C for 6 h (hippocampus) or 18 h (cortex). The samples were placed in Trump's fixative overnight at 4 °C before being processed for routine transmission electron microscopy (dehydration by xylene-alcohol series, osmium tetroxide staining, and Epon resin embedding). Images were acquired and quantified using a Jeol 1400+ electron microscope with an 80-kV acceleration voltage. Two grids from each tissue were produced, and >100 cells were scanned per grid at a magnification of 20,000× to detect cells containing X-Gal crystals. On average, half of all cells examined were neurons. Cells with one or more crystals, and the total number of cells, were counted. Cells containing crystals were imaged and independently assessed for distinguishing morphology. To define cell type, the following criteria were applied. Astrocytes: circular nucleus with spattered electron density pattern; microglia: abnormally shaped nucleus with a much darker, often phagosome-containing cytoplasm; and neuron: large circular nucleus with less electron density and periodically denoted by an offshooting axon. Only cells with morphology consistent with astrocytes or microglia were clearly positive for X-gal crystals. Western blotting for soluble and sarkosyl insoluble proteins. Half brains were weighed and homogenized in 5× volume of Buffer I (50 mM Tris base (pH 7.4), 50 mM NaCl, 1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride (PMSF), 1× Halt Protease and Phosphatase Inhibitor Cocktail (Thermo)). Two hundred and fifty microlitres of the homogenate was then added to an equal volume of Buffer S (50 mM Tris (pH 8.0), 274 mM NaCl, 5 mM KCl, 1 mM PMSF, 1X Halt Protease and Phosphatase Inhibitor Cocktail (Thermo)) and ultracentrifuged at 150,000g for 15 min at 4 °C. The supernatant (S1-soluble protein fraction) was transferred to a new tube and the pellet homogenized in 3× volume of sucrose buffer (10 mM Tris (pH 7.4), 0.8M NaCl, 10% sucrose, 1 mM EGTA, 1 mM PMSF) before being ultracentrifuged at 150,000g for 15 min at 4 °C. The pellet was discarded and the supernatant incubated with sarkosyl (sodium lauroyl sarcosinate) at a final concentration of 1% for 1 h at 37 °C. After incubation, the samples were ultracentrifuged at 150,000g for 30 min at 4 °C. The supernatant was discarded and the pellet was resuspended in 25 μl Buffer F (10 mM Tris (pH 8.0), 1 mM EDTA) to obtain the insoluble protein fraction (S2). Equal parts of 2× laemmli buffer (Bio-Rad) containing 5% β-mercaptoethanol was added to each fraction (S1 and S2) and boiled at 100 °C for 15 min to prepare the sarkosyl-soluble and -insoluble protein lysates. For total protein lysate, 90 μl of the homogenate (half brain in 5X volume Buffer I) was added to 110 μl of Buffer T (2% SDS, 50 mM Tris (pH 7.4), 274 mM NaCl, 5 mM KCl, 5 mM EDTA, 1% Triton-X-100, 1 mM PMSF, X Halt Protease and Phosphatase Inhibitor Cocktail (Thermo)). The samples were then sonicated and centrifuged at 16,000g for 15 min at 4 °C to remove debris. The supernatant was removed and added to equal parts 2× laemmli buffer with 5% β-mercaptoethanol and boiled at 100 °C for 15 min to prepare the total protein lysate. Western blotting was performed as previously described 23 . Blots were probed with antibodies for total tau (Thermo Fisher; MN1000, 1:5,000) and phospho-tau S202/T205 (Thermo Fisher; MN1020, 1:1,000). Ponceau-S staining was performed to normalize lysate loading for the total-and S1-fraction lysates. Quantification was performed using ImageJ as previously described 3 . Quantitative RT-PCR. RNA extraction, cDNA synthesis and RT-qPCR analysis were performed on hippocampi and cortical samples from mouse brains as previously described 24 . Primers used to amplify Casp8, GFP, p16 Ink4a , p19 Arf , p21, Pai1, Il-6, Il-1b and Cd11b were as previously described 3, 5, 24 . The following additional primers were used: Gfap forward 5′-CCTTCTGACACGGATTTGGT-3′, reverse 5′-TAAGCTAGCCCTGGACATCG-3′; S100b forward 5′-CCGGAGTACTGG TGGAAGAC-3′, reverse 5′-GGACACTGAAGCCAGAGAGG-3′; Aqp4 forward 5′-TGAGCTCCACATCAGGACAG-3′, reverse 5′-TCCAGCTCGATCTT TTGGAC-3′; Cx3cr1 forward 5′-GTTCCAAAGGCCACAATGTC-3′, reverse 5′-TGAGTGACTGGCACTTCCTG-3′; Olig2 forward 5′-CCCCA GGGATGATCTAAGC-3′, reverse 5′-CAGAGCCAGGTTCTCCTCC-3′; Nefl forward 5′-AGGCCATCTTGACATTGAGG-3′, reverse 5′-GCAGAATGCAGAC ATTAGCG-3′; Tbp forward 5′-GGCCTCTCAGAAGCATCACTA-3′, reverse 5′-GCCAAGCCCTGAGCATAA-3′. Expression for all experiments was normalized first to Tbp. Immunohistochemistry and immunofluorescence staining. Mice were transcardially perfused as described in 'Senescence-associated β-galactosidase transmission electron microscopy (Gal-TEM)' . Brains were stored in 4% PFA overnight at 4 °C and then cryoprotected by incubating in a 30% sucrose solution for 48 h at 4 °C. Samples were sectioned into 30-μM-thick coronal sections and stored in antifreeze solution (300 g sucrose, 300 ml ethylene glycol, 500 ml PBS) at −20 °C. Nissl staining (bregma −2.1 to −2.4 mm), thioflavin S staining (bregma −1.4 to −1.6 mm), and phospho-tau S202/S205 (Thermo Fisher, MN1020; 1:500), phospho-tau T231 (Thermo Fisher, MN1040; 1:500), phospho-tau S396 (Abcam, 109390; 1:500), and GFAP (Dako, Z0334; 1:500) and IBA1 (Novus, NB100-1028; 1:100) immunohistochemistry staining (bregma 1.6 to 1.0 mm and lateral 2.0 to 2.7 mm) was performed on free-floating sections as described [25] [26] [27] . NeuN staining (EMD, MAB377; 1:200) of five sections (between bregma −1.3 to −2.5) to measure the dentate gyrus area was performed as previously described 28 . For cellular proliferation assays, mice were injected with EdU (Carbosynth, NE08701; 75 mg kg −1 ) intraperitoneally 24 h before euthanasia. Imaging of EdU-positive cells (lateral 0.75 to 1.25 mm) was performed following the manufacturer's instructions (Invitrogen Click-iT EdU Alexa Fluor 488 Imaging Kit, C10337). IBA1 (Wako, 019-19741; 1:500) immunofluorescent staining and IBA1/EdU colocalization assessments were performed as previously described 28 . TUNEL staining (lateral 0.75 to 1.25 mm) was performed according to the manufacturer's instructions (Roche In situ Cell Death Detection Kit, Fluorescein: 11684795910). Thioflavin S, EdU/IBA1 colocalization, and in vivo TUNEL-stained images were acquired on a Zeiss LSM 780 confocal system using multi-track configuration. Single-cell preparation and FACS. Dissociation of cerebral tissue was performed using the Adult Brain Dissociation kit from Miltenyi (MACS, 130-107-677), according to the manufacturer's instructions. Samples were then incubated with a viability dye, LIVE/DEAD Aqua (Invitrogen, L34966; 1:250) followed by incubation with CD11b eFluor 450 (eBioscience, 48-0112-80, 1:100), CD45 APC eFluor 780 (eBioscience, 47-0451-82; 1:200), Glast1 PE (Miltenyi Biotec, 130-095-821; 1:100), O1 AF 700 (R&D Systems, FAB1327N-100UG; 1:100) and CD56 APC (R&D Systems, FAB7820A; 1:100). These samples were then sorted using a FACSAria IIu SORP (BD Biosciences), with gating parameters created using FACSDiva 8.0.1 (BD Biosciences). A precise gating strategy was used to maximize the purification of each isolated cell population. In brief, populations were isolated first by a negative report of the viability dye indicating the cell is viable (Extended Data Fig. 4 ), followed by a positive report of the desired marker, then negative reports of the other labels used. This strategy allowed for live cells containing only the desired marker to be sorted, while eliminating dead cells. Cells were sorted directly into lysis buffer and RNA was extracted with RNeasy Micro kits according to the manufacturer's instructions (Qiagen, cat no. 74004). cDNA synthesis and RT-qPCR analysis were performed as described above. Novel-object recognition. Novel-object recognition testing was performed as previously described 15 . In brief, mice from each cohort were acclimatized to a 50 cm × 50 cm testing environment for a period of two minutes. After acclimatization, the mice were removed, the testing area was cleaned with 70% ethanol, and two Letter reSeArCH identical scented candles were placed in either corner of the testing area approximately 5 cm from either wall. Mice were reintroduced, and the ratio of both the number of visits and the time spent at each candle was recorded for a period of ten minutes. Recording was performed from above (Panasonic WV-CP294) and all video files were analysed with TopScan Version 3.00 (Clever Sys). Afterwards, the mice were removed, the testing area cleaned with 70% ethanol, and one candle was replaced with a novel scent. The mice were reintroduced and the number of visits and total time per candle was recorded as before. Testing was also performed with visual stimuli, by placing identical toy brick towers at either corner and then replacing with a different toy brick tower in the testing phase, using the same experimental paradigm monitoring for the number of investigations. In vitro astrocyte and microglia culture. Astrocyte and microglia primary cultures were prepared in tandem from mixed glial cultures as previously described 29 . C57BL/6 wild-type and ATTAC pups (postnatal day (P)0-P3) were euthanized, and the cerebellum was discarded. Meninges were removed from the remaning tissue using forceps and a dissection scope. Cleaned cerebral tissue was placed in chilled Earle's Balanced Salt Solution with HEPES (EBSH) (NaCl 120 mM, NaH 2 PO 4 10 mM, KCl 2.5 mM, C 6 H 12 O 6 20 mM, HEPES 20 mM, NaHCO 3 10 mM, BSA 0.3%, H 2 O) until the remaining mice were euthanized, and then mice were pooled together on the basis of genotype (3-4 brains per group). The tissue was minced using a razor blade and dissociated by shaking in a 0.025% Trypsin/ EBSH solution at 37 °C for 30 min. FBS and MgSO 4 (3.82%)/ DNase I (1 mg ml −1 ) were added, and the sample was placed on ice for 5 min to halt trypsinization. Samples were mixed and centrifuged at 200g at 25 °C for 5 min. The supernatant was discarded, and the remaining pellet was resuspended in EBSH. Tissue was triturated using a 1 ml pipette to completely dissociate the sample and allowed to settle for 5 min to remove large debris. Samples were then transferred to clean tubes and underlaid with a 4% BSA/EBSH solution. The tissue was then centrifuged at 100g at 25 °C for 8 min. Cells were counted using trypan blue and a haemocytometer and plated on a poly-d-lysine-coated T75 dish (7-10 million cells per flask) with glial cell culture medium (GCM) consisting of DMEM with 10% FBS, sodium pyruvate (1 mM), Pen/Strep (500 μg ml −1 ), and InvivoGen Primocin (100 μg ml −1 ). Cultures were grown for 14 days (37 °C, ambient O 2 ) with medium changes every 4 days. Microglia were isolated as previously described 30 using the EasySep Mouse CD11b Positive Selection Kit from Stem Cell (cat. no. 18970). Microglia were collected and plated on 10-well glass slides (5,000 cells per well) and cultured for 6 days in GCM with LADMAC-conditioned medium (20%, provided by the Howe laboratory) before further experimentation. This conditioned medium aids in the proliferation and maintenance of microglia cultures through the secretion of macrophage colony-stimulating factor by the LADMAC cells 31 . Microglia were allowed to proliferate for 6 days before experimentation. The mixed glial culture flow-through from the EasySep CD11b kit was replated in GCM on a poly-d-lysine-coated T75 dish (10 million cells per flask). These cultures then underwent purification for astrocytes as previously described 29 . After 48 h, flasks were placed on an orbital shaker and agitated at 200 r.p.m. for two 24-h periods with medium refreshed once during and after the shaking. Flasks were then exposed to GCM containing liposomal clodronate (Clodrosome, 8909; 100 μg ml −1 ) for 72 h to remove any remaining microglia from the culture. The liposomal clodronate medium was then removed and culture plates washed before further experimentation. Microglia activation and TUNEL staining. Microglia samples were exposed to medium containing IFNγ (R&D Systems, 285-IF; 200 ng ml −1 ), lipopolysaccharides (LPS) (Sigma, L2654; 100 ng ml −1 ) or a combination of both for a period of 24 h to induce an inflammatory response 32 . Cells were then processed for immunofluorescence to determine inflammation state as previously described 33 . Anti-CD11b antibody (Bio-Rad, MCA711G; 1:500) and goat anti-rat AlexaFluor 594 (Invitrogen, A-11007; 1:500) staining was counterstained with DAPI (Invitrogen, D1306; 1:1,000). To assess AP-mediated cell clearance specificity, activated or basal microglia were exposed to AP20187 (Clontech, 635059; 10 nM or 100 nM) for a period of 24 h. TUNEL staining was then performed according to the manufacturer's instructions (Roche In situ Cell Death Detection Kit, Fluorescein: 11684795910). All imaging was performed using an Olympus BX53 Fluorescence microscope and DP80 digital camera. Analysis was performed using the Fiji distribution of ImageJ (version 1.51n) 34 . To obtain a TUNEL positive percentage, a region of interest was defined using Li Auto Thresholding of the DAPI channel, and the colocalization percentage was calculated using the colocalization threshold plugin bound by that region. IncuCyte tracking of basal and activated astrocytes. To track basal and activated astrocytic response to AP, astrocytes were plated in a 48-well culture plate (10,000 cells per well) and placed into the IncuCyte S3 Live-Cell Analysis System. The IncuCyte System is a time-lapse imaging system that records changes in cell culture through photographic capture of the culture well within the incubator. Cultures were acclimatized to the system for a period of 6 h, then exposed to medium containing IFNγ (R&D Systems, 285-IF; 200 ng ml −1 ), LPS (Sigma, L2654; 100 ng ml −1 ) or a combination of both for a period of 24 h to induce an inflammatory response 35 . Cells were also plated on 10-well slides and processed in tandem for immunofluorescence staining to verify activation status with anti-GFAP (DAKO, Z0334; 1:500) and counterstained with DAPI (Invitrogen, D1306; 1:1,000). After activation, astrocytes were exposed to AP20187 (Clontech, 635059; 10 nM or 100 nM) for a period of 24 h. The IncuCyte-captured phase images of each culture well were taken every 30 min over this period using the following settings: segmentation adjustment: 0.8, hole fill: 450, adjust size (pixels): −1, Minimum area (μm 2 ): 0.1. The phase confluency difference was calculated by subtracting the final phase confluency of each image from its initial value. Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this paper.
Extended Data Fig. 1 | Senescent cells accumulate in PS19 mice.
RT-qPCR analysis of senescence-associated genes in hippocampi (left) and cortices (right) of three-and ten-month-old male mice. Number of mice is as indicated, two independent experiments; normalized to the three-month wild-type group. Data are mean ± s.e.m. *P < 0.05; **P < 0.01; ***P < 0.001 (one-way ANOVA with Tukey's multiple comparisons test).
Exact P values can be found in the accompanying Source Data. test (b, d) ). Exact P values can be found in the accompanying Source Data.
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Extended Data Fig. 10 | Vision-based novel-object discrimination remains intact in AP-treated PS19;ATTAC mice. Objects used for novel-object recognition during the training and testing phases for visual discrimination (left) and the average ratio for the number of investigations (right, n = 8 female mice per group). Data are mean ± s.e.m. **P < 0.01; ***P < 0.001 (two-way ANOVA with Tukey's multiple comparisons test).
Exact P values can be found in the accompanying Source Data.
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